# Metabolic Peptide FAQ — Semaglutide, Tirzepatide, Retatrutide — Peptide Mundo

> Frequently asked questions about three Metabolic & Weight Research incretin peptides — semaglutide, tirzepatide, and retatrutide — answered from the peer-reviewed literature, with citations.

Direct, citation-anchored answers to the questions readers most often bring to these three incretin-class metabolic peptides.

## What is semaglutide?

Semaglutide is a synthetic peptide that acts as a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, one of the gut hormones released after eating. It is FDA-approved for type 2 diabetes mellitus, chronic weight management, reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and (since 2025) metabolic dysfunction-associated steatohepatitis (MASH). It is available as a once-weekly subcutaneous injection and a once-daily oral tablet [4][5]. Semaglutide is a prescription medicine, not a research-only compound.

## What is semaglutide used for?

Clinical uses supported by FDA approval include: lowering blood glucose in type 2 diabetes mellitus, reducing body weight in chronic weight management (at the higher 2.4 mg weekly dose), reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and treating metabolic dysfunction-associated steatohepatitis [3][4]. In research, it has also been studied for kidney-disease event reduction in type 2 diabetes with CKD, where it reduced the primary renal composite outcome by 24% versus placebo in the FLOW trial [2]. All uses described here are documented from published clinical trials.

## How does semaglutide work for weight loss?

Semaglutide activates GLP-1 receptors in hypothalamic and brainstem appetite circuits — particularly the arcuate nucleus and area postrema. This activates neurons that signal fullness (POMC/CART) and suppresses neurons that drive hunger (NPY/AgRP), reducing overall food intake and — in patient reports — the intrusive background preoccupation with food that people describe as "food noise." It also slows gastric emptying, extending the sensation of fullness after meals. The weight effect is primarily central rather than metabolic: it makes people want to eat substantially less [4].

## What is tirzepatide?

Tirzepatide is a 39-amino-acid synthetic peptide that simultaneously activates two incretin receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It is described as a dual receptor agonist or "twincretin." It is FDA-approved for type 2 diabetes mellitus, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity. In vitro receptor assays show it engages the GIP receptor more potently than the GLP-1 receptor and exhibits biased GLP-1R signaling that favors cAMP over beta-arrestin [6][10].

## How does tirzepatide work?

By engaging GIP and GLP-1 receptors together, tirzepatide potentiates glucose-dependent insulin secretion from pancreatic beta cells (through both receptor arms), suppresses glucagon from alpha cells, and slows gastric emptying — the shared GLP-1 pharmacology that drives appetite suppression and the GI side-effect profile. The GIP arm adds incrementally in central appetite circuits and possibly in adipose tissue. In head-to-head comparison with a selective GLP-1 agonist, tirzepatide produced greater weight loss (-20.2% versus -13.7% at 72 weeks), supporting the additive or synergistic model of dual-receptor engagement [1][11].

## What does tirzepatide do in the body?

In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon — the combined effect is improved blood-sugar control without meaningful hypoglycemia risk when used alone. In the gut, it slows gastric emptying, contributing to prolonged satiety and nausea as a side effect. In the brain, it acts on appetite-regulating hypothalamic circuits to reduce hunger and food-seeking behavior. In the liver and elsewhere, pleiotropic effects are being evaluated in ongoing trials. A SURMOUNT-1 DXA substudy found approximately 75% of weight lost was fat mass and approximately 25% was lean mass — a body-composition shift broadly consistent with weight loss by other means [8].

## What is tirzepatide used for?

FDA-approved indications: type 2 diabetes mellitus (since May 2022), chronic weight management in adults with obesity or overweight with a weight-related condition (since November 2023), and moderate-to-severe obstructive sleep apnea in adults with obesity. In clinical research it has also been studied in SURPASS-2 versus semaglutide 1 mg in type 2 diabetes [9], and SURMOUNT-5 provides the head-to-head obesity weight-loss comparison against semaglutide 2.4 mg [1]. It is a prescription medicine, not available for self-administration outside of medical supervision.

## What does retatrutide do?

Retatrutide activates three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). The GLP-1 and GIP arms suppress appetite and enhance glucose-dependent insulin secretion; the glucagon arm adds thermogenic energy expenditure and lipid mobilization. In Phase 2, 12 mg over 48 weeks produced -24.2% mean body weight in adults with obesity — the largest Phase 2 weight-loss figure reported for any incretin agent [15]. A Phase 2 substudy in metabolic liver disease found 86% of participants reached normal liver fat at 24 weeks [14]. Retatrutide is investigational; these are Phase 2 results, not approved-label data.

## How does retatrutide work?

Retatrutide's pharmacology adds a third dimension to the dual-agonist mechanism: glucagon receptor activation. While GLP-1/GIP agonism primarily reduces food intake (energy in), the glucagon arm increases energy expenditure (energy out) through brown-adipose-tissue thermogenesis and fatty-acid oxidation. This combination acts on both sides of the energy equation simultaneously. A 2025 review of the triple-agonist pharmacology and Phase 1/2 data characterizes this as mechanistically distinct from dual agonism, and the ~24% Phase 2 weight loss is described as a step-change versus prior incretin agents [12]. Cryo-EM structural work confirms retatrutide engages all three receptor complexes, with distinct binding modes at each [13].

## Is retatrutide FDA approved?

No. Retatrutide is not approved by the FDA or any other regulatory agency as of mid-2026. It is an investigational compound being studied in Phase 3 clinical trials (the TRIUMPH program). All efficacy and safety data currently available are from Phase 1 and Phase 2 studies. The FDA issued enforcement actions against vendors selling "research-grade" retatrutide outside clinical trials in 2025. Retatrutide is available legally only to participants in registered clinical trials [12][15].

## How do semaglutide and tirzepatide compare in weight loss?

The SURMOUNT-5 trial directly compared the two in 751 adults with obesity and no type 2 diabetes over 72 weeks, using each drug's maximum tolerated dose. Tirzepatide produced -20.2% mean weight loss versus -13.7% with semaglutide — a statistically significant difference of approximately 6.5 percentage points (P<0.001). Tirzepatide also produced greater reductions in waist circumference and higher proportions of participants reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss. This is the most robust available head-to-head comparison [1].

## Are these peptides safe?

Semaglutide and tirzepatide have established clinical-trial safety profiles with FDA approval, but "safe" is not a categorical statement. Both carry boxed warnings regarding thyroid C-cell tumors (based on rodent data, with the human signal unconfirmed). Both have dose-related gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) that are the dominant cause of discontinuation. Both are associated with gallbladder and biliary disease risk. Lean-mass loss accompanies fat loss. Weight regain after stopping is substantial. Retatrutide has an additional documented dose-dependent heart-rate increase and no long-term outcomes data, and its investigational status means gray-market material cannot be verified for identity, purity, or sterility [5][7][12][15]. This desk reports these findings factually; it does not advise on safety for any individual, which requires a licensed clinician.

---

A peer-reviewed literature digest on incretin-class metabolic peptides — citations and context, not clinical counsel.